Concepedia

Mark L. Zangardi

ML

Statistics

Publications

4

Citations

246

H-Index

4

Active since

2017

Affiliations

Massachusetts General Hospital(Current)

Harvard University

Washington University in St. Louis

Baylor University Medical Center

Texas Oncology

Mark L. Zangardi is an author at Massachusetts General Hospital specializing in medicine, pathology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2017–2021

4

Publications

4

Ruxolitinib for secondary hemophagocytic lymphohistiocytosis

Jonathan H. Sin, Mark L. Zangardi · Hematology/Oncology and Stem Cell Therapy · 2017 · 86 citations · Full text

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi et al. · Journal of the National Comprehensive Cancer Network · 2021 · 82 citations

Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer

Ryan David Nipp, Margaret Ruddy, Charn‐Xin Fuh et al. · The Oncologist · 2018 · 42 citations · Full text

A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).

Seth A. Wander, Mark L. Zangardi, Andrzej Niemierko et al. · Journal of Clinical Oncology · 2019 · 36 citations

, , +20

Rows per page

1–4 of 4